Printer Friendly

SEARLE REDUCES OPERATING COSTS WITH SALE OF MANUFACTURING FACILITY LOCATED AT LANDEN, BELGIUM

 CHICAGO, Sept. 13 /PRNewswire/ -- Searle announced today that it has completed the sale of a chemical manufacturing facility located at Landen, Belgium, to Conti BPC, which is controlled by Irotec, a manufacturer of bulk pharmaceutical chemicals, headquartered in Cork, Ireland.
 Searle announced its intent to sell the Landen facility in February as part of a worldwide restructuring plan to reduce operating costs to remain competitive in the global marketplace for pharmaceuticals.
 Products now being manufactured at Landen will be transferred to other Searle facilities worldwide or will be produced under contractual arrangements with Conti BPC. Sufficient capacity exists at other Searle facilities to efficiently meet demand for Searle's new products: Maxaquin(R), Daypro(TM) and Arthrotec(R).
 Current employment at Landen is 93; all employees will be retained by Conti BPC. Financial details of the transaction are not being disclosed.
 Searle is a research-based developer, manufacturer and marketer of prescription drugs worldwide. It is a wholly owned subsidiary of the Monsanto Company (NYSE: MTC).
 -0- 9/13/93
 /CONTACT: Jack Domeischel, 708-470-6720, or Jeff Newton, 708-470-6280, both of Searle/
 (MTC)


CO: Searle; Monsanto Company ST: Illinois IN: MTC SU:

SH -- NY078 -- 1376 09/13/93 14:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:198
Previous Article:AMERICAN EXPRESS CORPORATE CARD EXPANDS MARKETING CAMPAIGN
Next Article:VIACOM $450 MILLION 'BB+' SUBORDINATED DEBT ON FITCHALERT POSITIVE -- FITCH FINANCIAL WIRE --
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters